NEW YORK, NY / ACCESSWIRE / March 31, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

HP Inc. (NYSE:HPQ)
Class Period: February 23, 2017 to October 3, 2019
Lead Plaintiff Deadline: April 20, 2020

According to the filed complaint, defendants knew that HP's "four-box" model for measuring its supplies business was severely deficient and not a strong predictor of supplies demand and outcomes because HP lacked telemetry data from its commercial printers and had to use unreliable and stagnant market share data to develop assumptions for the four-box model. The complaint further alleges that defendants knew the lack of telemetry data for commercial printing was a critical shortcoming of the four-box model because HP possessed telemetry data on its personal printing side and knew it was a necessary element for an accurate understanding of the supplies channel. As a result, the supplies inventory in the Company's channel exceeded demand by at least $100 million and HP's supplies revenue growth was grossly inflated.

Learn about your recoverable losses in HPQ: http://www.kleinstocklaw.com/pslra-1/hp-inc-loss-submission-form?id=5861&from=1

Jeld-Wen Holding, Inc. (NYSE:JELD)
Class Period: January 26, 2017 to October 15, 2018
Lead Plaintiff Deadline: April 20, 2020

Throughout the class period, Jeld-Wen Holding, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's products, including doors, did not compete against other manufacturers on price, contrary to Jeld-Wen's representations; (2) the market in which the Company sells its doors is not "highly competitive" as the Company claimed; (3) Jeld-Wen's strong margins and anticipated margin growth were not, as the Company claimed, attributed to changes they had made in Jeld-Wen's business operations and strategies; and (4) Jeld-Wen failed to disclose the Company's anti competitive conduct. Because of the foregoing, Defendants' statements about the Company's business, operations and prospects lacked a reasonable basis.

Learn about your recoverable losses in JELD: http://www.kleinstocklaw.com/pslra-1/jeld-wen-holding-inc-loss-submission-form?id=5861&from=1

Tilray, Inc. (NASDAQ:TLRY)
Class Period: January 15, 2019 to March 2, 2020
Lead Plaintiff Deadline: May 5, 2020

The TLRY lawsuit alleges Tilray, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) the purported advantages of the marketing and revenue sharing agreement with Authentic Brands Group (the "ABG Agreement")were significantly overstated; (ii) the under performance of the ABG Agreement would foreseeably have a significant impact on the Company's financial results; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in TLRY: http://www.kleinstocklaw.com/pslra-1/tilray-inc-loss-submission-form?id=5861&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 583314

NEW YORK, NY / ACCESSWIRE / March 31, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

WWE Shareholders Click Here: https://www.zlk.com/pslra-1/world-wrestling-entertainment-inc-loss-form?prid=5860&wire=1
TVTY Shareholders Click Here: https://www.zlk.com/pslra-1/tivity-health-inc-loss-form?prid=5860&wire=1
AAN Shareholders Click Here: https://www.zlk.com/pslra-1/aarons-inc-loss-form?prid=5860&wire=1

* ADDITIONAL INFORMATION BELOW *

World Wrestling Entertainment, Inc. (NYSE:WWE)

WWE Lawsuit on behalf of: investors who purchased February 7, 2019 – February 5, 2020
Lead Plaintiff Deadline : May 5, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/world-wrestling-entertainment-inc-loss-form?prid=5860&wire=1

According to the filed complaint, during the class period, World Wrestling Entertainment, Inc. made materially false and/or misleading statements and/or failed to disclose that: Defendants perpetrated a fraudulent scheme which: (i) deceived the investing public regarding WWE's business and prospects; (ii) artificially inflated the price of WWE Class A common stock; (iii) permitted certain senior executives of WWE to sell more than $282 million worth of their personally held shares at fraud inflated prices; and (iv) caused the public to purchase WWE Class A common stock at artificially inflated prices.

Tivity Health, Inc. (NASDAQ:TVTY)

TVTY Lawsuit on behalf of: investors who purchased March 8, 2019 – February 19, 2020
Lead Plaintiff Deadline : April 27, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/tivity-health-inc-loss-form?prid=5860&wire=1

According to the filed complaint, during the class period, Tivity Health, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) following the Nutrisystem Acquisition, Tivity's Nutrition segment faced significant operational challenges; (ii) the foregoing would foreseeably have a significant impact on Tivity's revenues; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Aarons, Inc. (NYSE:AAN)

AAN Lawsuit on behalf of: investors who purchased March 2, 2018 – February 19, 2020
Lead Plaintiff Deadline : April 28, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/aarons-inc-loss-form?prid=5860&wire=1

According to the filed complaint, during the class period, Aarons, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Aaron's had inadequate disclosure controls, procedures, and compliance measures; (ii) consequently, the operations of Aaron's Progressive Leasing ("Progressive") and Aaron's Business ("AB") segments were in violation of the Federal Trade Commission ("FTC") Act and/or relevant FTC regulations; (iii) consequently, Aaron's earnings from those segments were partially derived from unlawful business practices and were thus unsustainable; (iv) the full extent of Aaron's liability regarding the FTC's investigation into its Progressive and AB segments, Aaron's noncompliance with the FTC Act, and the likely negative consequences of all the foregoing on the Company's financial results; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 583313

VANCOUVER, BC / ACCESSWIRE / March 31, 2020 / Emerald Health Therapeutics, Inc. ("Emerald") (TSXV:EMH; OTCQX:EMHTF) announced that its Pure Sunfarms ("PSF") joint venture has expanded its credit facility with its existing lender to $59 million, including accordion provisions of $22.5 million. The expanded credit facility (the "Credit Facility") consists of a $7.5 million revolving operating loan (the "Revolver") and a $10 million term loan (the "New Term Loan"), in addition to its existing $19 million term loan (the "Existing Term Loan"). The New Term Loan is specifically designated for the 1.1 million square foot Delta 2 greenhouse while the Existing Term Loan is specifically designated for the 1.1 million square foot Delta 3 greenhouse facility.

The $7.5 million Revolver and the $10 million New Term Loan include an accordion provision that allows Pure Sunfarms to request additional lender commitments of up to an additional $7.5 million and $15 million, respectively, subject to an additional lender entering the syndicate on or before May 30, 2020. Each of the components of the Credit Facility, including the Existing Term Loan, mature on February 7, 2022.

The finalization of the Credit Facility is subject to Pure Sunfarms satisfying certain pre-conditions including an additional capital contribution by Village Farms International, Inc. ("Village Farms") of $8 million ("Additional Capital Contribution"), which is expected to be completed this week. Upon completion of the Additional Capital Contribution, Emerald's equity position in Pure Sunfarms will be reduced by 1.3% to 41.3%. Emerald continues to hold three of six seats on Pure Sunfarms' Board of Directors.

"With Pure Sunfarms achieving notable retail sales and operational success in a very short timeframe, access to this additional capital will allow it to continue developing its leadership in its targeted segment of the Canadian cannabis marketplace," said Riaz Bandali, President and CEO, Emerald Health Therapeutics.

About Emerald Health Therapeutics

Emerald Health Therapeutics, Inc. is committed to cutting-edge cannabis science to create new consumer experiences with distinct recreational, medical and wellness-oriented cannabis and non-cannabis products. With an emphasis on innovation and production excellence, Emerald's three distinct operating assets are designed to uniquely serve the Canadian marketplace and international opportunities. These assets, all in full production, include: its Richmond, BC-based organic-certified greenhouse operation (78,000 square feet); Verdélite, its premium craft cannabis production indoor facility in St. Eustache, Québec (88,000 square foot); and Pure Sunfarms, its 42.6%-owned joint venture in Delta, BC, producing high quality, affordably priced products (1.1 million square feet). Its Emerald Naturals joint venture has launched a new natural wellness product category with its non-cannabis endocannabinoid-supporting product line and is expanding distribution across Canada.

Please visit www.emeraldhealth.ca for more information or contact:

Jenn Hepburn, Chief Financial Officer
(800) 757 3536 Ext. #5

Emerald Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements.

We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, changes of law and regulations; changes of government; failure to obtain regulatory approvals or permits; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; failure of counter-parties to perform contractual obligations; as well as the risk factors described in Emerald's annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. Emerald undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

SOURCE: Emerald Health Therapeutics, Inc.

ReleaseID: 583308

NEW YORK, NY / ACCESSWIRE / March 31, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

CRON Shareholders Click Here: https://www.zlk.com/pslra-1/cronos-group-inc-loss-form-2?prid=5859&wire=1
ANAB Shareholders Click Here: https://www.zlk.com/pslra-1/anaptysbio-inc-loss-form?prid=5859&wire=1
HAFC Shareholders Click Here: https://www.zlk.com/pslra-1/hanmi-financial-corporation-loss-form?prid=5859&wire=1

* ADDITIONAL INFORMATION BELOW *

Cronos Group Inc. (NASDAQ:CRON)

CRON Lawsuit on behalf of: investors who purchased May 9, 2019 – March 2, 2020
Lead Plaintiff Deadline : May 11, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/cronos-group-inc-loss-form-2?prid=5859&wire=1

According to the filed complaint, during the class period, Cronos Group Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Cronos had engaged in significant transactions for which its revenue recognition was inappropriate; (ii) the foregoing would foreseeably necessitate reviews that would delay the Company's ability to timely file its periodic reports; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

AnaptysBio, Inc. (NASDAQ:ANAB)

ANAB Lawsuit on behalf of: investors who purchased October 10, 2017 – November 7, 2019
Lead Plaintiff Deadline : May 26, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/anaptysbio-inc-loss-form?prid=5859&wire=1

According to the filed complaint, during the class period, AnaptysBio, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) AnaptysBio failed to disseminate important data from the Company's Phase 2a trial in atopic dermatitis, including the timing and extent of patients' use of topical corticosteroids as a rescue therapy during the study and whether any of the patients that utilized rescue therapy were classified as responders at a given time;and (ii) the Company's statements omitted key information from the Company's Phase 2a trial in peanut allergy, including patients' average cumulative peanut dose tolerated at day 14 after the administration of etokimab or placebo as well as whether the Company's decision to exclude 20% of the patients enrolled in the study from the interim analysis due to their mild symptoms was retrospective; and (ii) as a result of the foregoing, Defendants' positive statements about the efficacy and prospects of AnaptysBio's lead drug asset in the treatment of atopic dermatitis and peanut allergy were materially false and/or misleading and/or lacked a reasonable basis.

Hanmi Financial Corporation (NASDAQ:HAFC)

HAFC Lawsuit on behalf of: investors who purchased August 12, 2019 – January 28, 2020
Lead Plaintiff Deadline : May 26, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/hanmi-financial-corporation-loss-form?prid=5859&wire=1

According to the filed complaint, during the class period, Hanmi Financial Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) the $40.7 million troubled loan that the Company disclosed on conference calls would necessitate further and future specific provisions for the Company – in the millions; (2) the same $40.7 million troubled loan would necessitate the Company to appraise and take personal property securing a portion of the amount of the loan; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 583312

NEW YORK, NY / ACCESSWIRE / March 31, 2020 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Norwegian Cruise Line Holdings Ltd. (NYSE:NCLH)
Class Period: February 20, 2020 – March 12, 2020
Deadline: May 11, 2020
For more info: www.bgandg.com/nclh.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: 1) Norwegian was employing sales tactics of providing customers with unproven and/or blatantly false statements about COVID-19 to entice customers to purchase cruises, thus endangering the lives of both their customers and crew members; and (2) as a result, defendants' statements regarding Norwegian's business and operations were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO)
Class Period: February 14, 2020 – March 9, 2020
Deadline: May 11, 2020
For more info: www.bgandg.com/ino

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements about Inovio's development of a purported vaccine for the novel coronavirus, artificially inflating the company's share price and resulting in significant investor losses.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 583041

Market players will witness future growth and enhance revenues by divesting from traditional manufacturing methods and leveraging the technological advancements

ROCKVILLE, MD / ACCESSWIRE / March 31, 2020 / The global silicon carbide market will witness stellar growth at a CAGR of 15% during 2019 – 2029, as projected by a new Fact.MR report. Key players in the silicon carbide market are eying profitable opportunities by leveraging on the sprouting demand for compact systems, motor drivers, and radiofrequency devices.

"Skyrocketing consumer demand in emerging economies and governments across the world supporting FDI investments are further complementing market growth," says the report.

Silicon Carbide Market: Key Findings

Black silicon carbide will quadruple its market value and continues holding more than half of the overall market share owing to increasing usage in automotive, steel, and construction industries.
Electrical & electronics will triple their share in the end-use segment, on the back of silicon carbide's physical properties which make it an ideal raw material for electrical and electronics applications
APAC (East Asia, South East Asia, and Oceania) will account for more than 50% of the global market value. This growth is invigorated by emerging economies such as China, India, and Indonesia, where the developing automotive manufacturing is employing silicon carbide in EV batteries.
Increasing applications in plug-in hybrid (PHEV) and electric vehicles (EV) are expected to enhance revenues from the automotive sector.

Request Sample Report-

https://www.factmr.com/connectus/sample?flag=S&rep_id=4581

Silicon Carbide Market: Key Driving Factors

A positive trend in electric vehicles manufacturing is pushing demand for silicon carbide as they prevent loss of charge and ensure the vehicles run for longer distances, thereby supporting the rise of the market.
Booming automotive industry in developing nations such as China is creating revenue opportunities for market players to cater to the burgeoning consumer demand
Governments in emerging economies supporting FDI investments are garnering significant attention from prominent SiC manufacturers.
Furthermore, incentive policies in developing countries are acting as a catalyst for high growth opportunities for innovators.

Silicon Carbide Market: Key Restraint

The high-cost associated devices made from silicon carbide possess a challenge to restrict rapid growth.

Explore the complete silicon carbide market report with detailed market segmentation, 195 illustrative figures, and 98 data tables at –

https://www.factmr.com/report/4581/silicon-carbide-market

Competition Landscape

Some key players in the silicon carbide market are Dow Chemical Co., AGSCO Corporation, Carborundum Universal Limited., Entegris Inc., ESD-SiC b.v., ESK-SIC GmbH, Gaddis Engineered Materials, Grindwell Norton Ltd., Saint Gobain Ceramic Materials GmbH, and Snam Abrasives Pvt. Ltd, among others. The market players are investing in research and development activities to gain traction among consumers.

About the Report:

Fact.MR presents a detailed and unbiased analysis of the global silicon carbide market, displaying data on historical demand (2014-2018) and forecast data for the period, 2019-2029. To simplify the vast study, the report is segmented on the basis of product (black silicon and green silicon), application (steel, automotive, aerospace, military & defense, electrical & electronics, healthcare, and others), and across 6 key regions (North America, Latin America, Europe, East Asia, South Asia & Oceania, and Middle East & Africa).

Explore Fact.MR's Comprehensive Coverage on Chemicals & Materials Landscape

Thermal Conductive Adhesives Market – Learn more about the major influencing factors affecting the thermal conductive adhesives market which is set for strong growth during the projection period (2019-2029).

Flame Retardant Coating Additives Market– Acquire in-depth insights about the Flame Retardant Coating Additives Market market through Fact.MR's detailed report covering end-use segments, market dynamics, recent material developments and prominent market players for the forecast period of 2019-2029.

Nylon Market– Obtain Fact.MR's exhaustive analysis on the global nylon market spanning dynamic market factors, key trends and successful strategies of market leaders projected for 2019-2027.

About Fact.MR

Expert analysis, actionable insights, and strategic recommendations of the veteran research team at Fact.MR helps clients from across the globe with their unique business intelligence requirements. With a repository of over a thousand reports and 1 million+ data points, the team has scrutinized the Chemicals & Materials sector across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services. Fact.MR's latest chemical market research reports and industry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition.

Contact:

Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
PR- https://www.factmr.com/media-release/1354/global-silicon-carbide-market

SOURCE: FactMR

ReleaseID: 583311

ELKO, NV / ACCESSWIRE / March 31, 2020 / Lithium Corporation (OTCQB:LTUM) ("LTUM" or "the Company"), a North American company focused on energy metals for the growing energy storage sector and high tech industries, is pleased to announce the Company's 25% owned subsidiary Summa, LLC (Summa) has signed the definitive agreement with 1237025 Nevada Ltd, (123 NV) wherein 123 NV can earn a 100% interest in Summa's property in Tonopah, Nye County Nevada, subject to a 1.00% Net Smelter Revenue interest by issuing cash and shares at predetermined intervals, and by performing work on the property.

123 NV recently issued $25,000 worth of stock, and $25,000 in cash to Summa as consideration for the signing of the agreement, and under the agreement 123 NV will pay $75,000 in cash, and $75,000 in shares annually in unequal semi-annual installments over the next five years. Additionally 123 NV must perform $1.5 million dollars worth of work on the property over five years. Summa will retain a 1.00% Net Smelter Revenue royalty on the property once 123 NV has earned its interest, however 123 NV may purchase 0.25% of this royalty for $1,500,000 and may then at its option purchase a further 0.25% of the royalty for $2,500,000. Lithium Corporation staff will continue to provide consultative services to 123 NV on an as-needed basis.

The Hughes Tonopah property features the eastern portion of the famous past-producing Tonopah mining district. Available historical data show the property contains dozens of mineralized zones consisting of epithermal quartz-calcite veins, stockworks and breccias hosted in intermediate and felsic volcanic rocks. The most significant past-producer on the property is the Belmont Mine which is reported to have produced 36.7 million ounces of silver and 428,000 ounces of gold at a silver equivalent grade of approximately 36.46 oz/t (1,250 g/t) Ag. Since mining ceased in 1929 very little modern exploration or assessment of remaining potential has been completed.

Lithium Corporation is complying with all governmental restrictions and suggestions with respect to endeavoring to limit the spread of the Corona Virus, and has restricted all but the most essential of travel at this point. However it is business as usual for the Company, and we remain committed to working through this difficult and trying period as best we can.

About Lithium Corporation

Lithium Corporation is an exploration company based in Nevada devoted to the exploration for energy storage related resources throughout North America, and looking to capitalize on opportunities within the ever-expanding next generation energy storage markets. The Company maintains a strategic alliance with Altura Mining, an ASX listed Lithium mining company that is currently producing at near nameplate capacity at its 100% owned world-class Pilgangoora lithium pegmatite mine in Western Australia. Website: www.lithiumcorporation.com

Contact Info

Tom Lewis, CEO
Lithium Corporation
775-410-5287
info@lithiumcorporation.com

Notice Regarding Forward-Looking Statements

This current report contains "forward-looking statements," as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future.

Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with mineral exploration and difficulties associated with obtaining financing on acceptable terms. We are not in control of minerals prices and these could vary to make development uneconomic. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our most recent annual report for our last fiscal year, our quarterly reports, and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

SOURCE: Lithium Corporation

ReleaseID: 583135

WALTHAM, MA / ACCESSWIRE / March 31, 2020 / Tecogen Inc. (NASDAQ:TGEN) will host a conference call for investors to discuss the status of the Company business as it relates to the Coronavirus restrictions. Company CEO, Benjamin M. Locke, will provide the update at 11:00AM (EST) on April 1st, 2020.

The conference call will be available live via telephone. To listen to the audio, dial (877) 407-7186 within the US and Canada or (201) 689-8052 from other international locations. Participants should ask to be joined to the Tecogen company update. Please begin dialing at least 10 minutes before the scheduled starting time.

The conference call will be recorded and available for playback one hour after the end of the call. To listen to the playback dial (877) 660-6853 within the US and Canada or (201) 612-7415 from other international locations. Use Conference Call ID #: 13672659. The replay will be available for 14 days following the call.

CONTACT:

Benjamin Locke
P: 781-466-6402
E: benjamin.locke@tecogen.com

SOURCE: Tecogen, Inc.

ReleaseID: 583306

ST. JOHN'S, NL / ACCESSWIRE / March 31, 2020 / Sokoman Minerals Corp. (TSXV:SIC)(OTCQB:SICNF) (the "Company" or "Sokoman") is pleased to provide an update on its winter exploration program at the Moosehead Gold project.

Phase 5 Diamond Drilling

The Company has completed the minimum 3,000 m commitment for the Phase 5 drilling and has ceased field operations for the spring break-up period. The Phase 5 program consisted of 13 drill holes totaling 3,229 metres. All holes reached their target depths except one land-based hole which was abandoned at 45 metres due to excessive deviation.

Seven holes were drilled from the ice on North Pond testing the extension of the upper, high-grade, shoots of the Eastern Trend. Visible gold bearing quartz veins and mineralized host rock were intersected on all four sections over core intervals ranging from less than a metre to approximately 8.0 metres (true thickness estimated at 75-90% of core intervals). The two discrete mineralized zones that were discovered during the 2019 ice program were intersected in the current program as well. They remain shallow – generally between 30-70 m vertical with visible gold on both structures. The current program has extended the Eastern Trend an additional 100 m to the north where it remains open. Core logging is not complete and the core intervals noted are subject to revision.

Land based drilling of the Eastern Trend focused on evaluating gold mineralization in the deepest mineralized shoot identified to date, at approximately 200 m vertical. Several holes were completed on the southern down-plunging portion of the shoot to infill a 75 metre gap between historical drill hole MH-03-15 (52.54 g/t Au / 2.34 m) and previously released Phase 4 drill hole MH-19-69a (18.10 g/t Au / 1.45 m including 82.17 g/t Au / 0.30 m). A single hole targeted the up-plunge portion of the lower shoot north of MH-19-62 (22.55g/t Au /7.20 m) and MH-20-81 (28.29 g/t Au/ 3.90 m). This shoot remains open both up-plunge to the north and down-plunge to the south and will be tested further in the next phase of drilling.

Due to the ongoing COVID-19 outbreak, core logging and sampling have temporarily been suspended and all staff have returned home. The Company has been informed by Eastern Analytical, the Springdale, NL-based laboratory providing analytical results, that work at the lab is continuing with a reduced workforce. As a result, there is no set timeline for the receipt, or release, of assay results from the drilling. Updated maps and sections will be posted once all logging and data entry have been completed.

Airborne Magnetic Survey

The Company is also pleased to report that it has received the final report from Prospectair on the high-resolution magnetic survey completed in January. The data is undergoing modeling and computer enhancement. Features requiring ground follow-up, once ground conditions permit, are already obvious.

Glacial Till Sampling

The initial results from the fall till sampling program have been received and will be merged with other existing geochemical data. This will then be combined with the high-resolution magnetic data to plan a prospecting, and possible trenching, field program for Q2 / Q3 2020. While approximately 50% of the samples have yet to be processed, several samples with strong gold grain counts from 54 to 63 grains with significant pristine / locally derived gold grains, warrant follow-up. These particular samples were collected from areas of the property with no or limited drilling and no previous gold mineralization noted. The contractor, Overburden Drilling Management of Ottawa, ON has informed Sokoman that the receipt of results will be affected by work slowdowns or stoppages in an effort to deal with the COVID-19 issue in a responsible manner.

Timothy Froude, P. Geo., President and CEO, comments: "While the pace of future work is currently uncertain, we are pleased with what we have accomplished with the Phase 5 drilling and other activities at Moosehead. We achieved our goal of 3,000+ metres drilled, with more than half of the holes drilled from the surface of the pond. The first till results from the 2019 program are encouraging, and together with the new airborne magnetic data, should provide an exciting follow-up program.

Sokoman will remain active evaluating results to date and planning future exploration, both at Moosehead and on our other projects. We will continue the modeling and interpretation of the Moosehead gold zones, as our geologists and consultants can work from home. As soon as conditions return to normal, we will once again ramp up our exploration efforts."

QP

This news release has been reviewed and approved by Timothy Froude, P. Geo., a "Qualified Person" under National Instrument 43-101 and President and CEO of Sokoman Minerals Corp.

About Sokoman Minerals

Sokoman Minerals Corp. is a discovery-oriented company with projects in Newfoundland & Labrador, Canada. The Company's primary focus is its portfolio of gold projects (Moosehead, Crippleback Lake and East Alder) in Central Newfoundland on the structural corridor hosting Marathon Gold's Valentine Lake project (with measured resources of 1.16 Moz. of gold at 2.18 g/t, indicated resources of 1.53 Moz. of gold at 1.66 g/t and inferred resources of 1.53 Moz. of gold at 1.77 g/t (Marathon Gold Website) 150 km southwest of the Company's high-grade Moosehead gold project*. The Company also has a 100% interest in an early-stage antimony/gold project in Newfoundland recently optioned to White Metal Resources Inc. In Labrador, the Company has a 100% interest in the Iron Horse (Fe) project.

The Company would like to thank the Government of Newfoundland and Labrador for financial support of the project through the Junior Exploration Assistance Program. The Company is applying for funding for the upcoming 2020 season as well.

*Mineralization hosted on adjacent and/or nearby properties is not necessarily indicative of mineralization hosted on the Company's property.

To learn more, please contact:

Timothy Froude, P. Geo.,
President & CEO
709-765-1726
tim@sokomanmineralscorp.com

Cathy Hume, Director,
Investor Relations
416-868-1079 x231
cathy@chfir.com

Website:
www.sokomanmineralscorp.com
Twitter: @SokomanMinerals
Facebook: @SokomanMinerals

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Investors are cautioned that trading in the securities of the Corporation should be considered highly speculative. Except for historical information contained herein, this news release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially. Sokoman Minerals Corp. will not update these forward-looking statements to reflect events or circumstances after the date hereof. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by Sokoman Minerals Corp.

SOURCE: Sokoman Minerals Corp.

ReleaseID: 583307

NEW YORK, NY / ACCESSWIRE / March 31, 2020 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against XP, Inc. ("XP" or "the Company") (NASDAQ:XP) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired XP securities pursuant and/or traceable to the registration statement and related prospectus (collectively, the "Registration Statement") issued in connection with XP's December 2019 initial public stock offering (the "IPO" or the "Offering"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/xp.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1933.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) XP engaged in undisclosed related party transactions; (2) XP failed to disclose its common and large system failures and connected losses; (3) XP's aggressive Independent Financial Agent strategy was and is tenuous; (4) XP had material weaknesses; (5) XP fired its previous accounting firm due that firm finding and disclosing material weaknesses; and (6) as a result, defendants' statements about XP's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/xp or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in XP you have until May 20, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 583045